source
- Cellares defends its cell therapy platform after Bristol Myers ends partnershipCellares, a cell therapy manufacturing startup, responded to criticism from Bristol Myers Squibb after the drugmaker terminated their agreement. Bristol Myers withdrew, saying Cellares' commercial…
- Industry groups call for clearer FDA guidance on QRIs in expedited IND pilotPharmaceutical trade groups have voiced concerns about the FDA's proposed expedited IND pilot, which aims to speed entry of drug candidates into first‑in‑human studies. The groups say the FDA need…